mTORC2 modulates feedback regulation of p38 MAPK activity via DUSP10/MKP5 to confer differential responses to PP242 in glioblastoma

Genes and Cancer

Volumn 5, Issue 11-12, 2014, Pages 393-406

  Benavides Serrato, Angelica ^a,c   Anderson, Lauren ^c   Holmes, Brent ^c   Cloninger, Cheri ^c   Artinian, Nicholas ^c   Bashir, Tariq ^a,c   Gera, Joseph ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

P38 MAPK DUSP mTOR

Indexed keywords

2 (4 AMINO 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 3 YL) 1H INDOL 5 OL; 2 MORPHOLINO 8 PHENYLCHROMONE; DUAL SPECIFICITY PHOSPHATASE; DUAL SPECIFICITY PHOSPHATASE 10; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS ASSAY; ARTICLE; CELL PROLIFERATION ASSAY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DRUG HALF LIFE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; HYBRIDIZATION; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; PLASMID; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN SYNTHESIS INHIBITION; RNA INTERFERENCE; TREATMENT RESPONSE; TUMOR XENOGRAFT; TUNEL ASSAY; WESTERN BLOTTING;

EID: 84939250655     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Cargnello M and Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev. 2011; 75(1):50-83.
2. Raingeaud J, Gupta S, Rogers JS, Dickens M, Han J, Ulevitch RJ and Davis RJ. Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem. 1995; 270(13):7420-7426.
3. Huang CY and Tan TH. DUSPs, to MAP kinases and beyond. Cell Biosci. 2012; 2(1):24.
4. Todd JL, Tanner KG and Denu JM. Extracellular regulated kinases (ERK) 1 and ERK2 are authentic substrates for the dual-specificity protein-tyrosine phosphatase VHR. A novel role in down-regulating the ERK pathway. J Biol Chem. 1999; 274(19):13271-13280.
5. Brondello JM, Pouyssegur J and McKenzie FR. Reduced MAP kinase phosphatase-1 degradation after p42/ p44MAPK-dependent phosphorylation. Science. 1999; 286(5449):2514-2517.
6. Laplante M and Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012; 149(2):274-293.
7. Wullschleger S, Loewith R and Hall MN. TOR signaling in growth and metabolism. Cell. 2006; 124(3):471-484.
8. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D and Shokat KM. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 2009; 7(2):e38.
9. Ma XM and Blenis J. Molecular mechanisms of mTORmediated translational control. Nat Rev Mol Cell Biol. 2009; 10(5):307-318.
10. Sarbassov DD, Guertin DA, Ali SM and Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictormTOR complex. Science. 2005; 307(5712):1098-1101.
11. Hung CM, Garcia-Haro L, Sparks CA and Guertin DA. mTOR-dependent cell survival mechanisms. Cold Spring Harb Perspect Biol. 2012; 4(12).
12. Kroemer G, Marino G and Levine B. Autophagy and the integrated stress response. Mol Cell. 2010; 40(2):280-293.
13. Jewell JL, Russell RC and Guan KL. Amino acid signalling upstream of mTOR. Nat Rev Mol Cell Biol. 2013; 14(3):133-139.
14. Sengupta S, Peterson TR and Sabatini DM. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell. 2010; 40(2):310-322.
15. Tomomori-Sato C, Sato S, Conaway RC and Conaway JW. Immunoaffinity purification of protein complexes from Mammalian cells. Methods Mol Biol. 2013; 977:273-287.
16. Gera JF, Hazbun TR and Fields S. Array-based methods for identifying protein-protein and protein-nucleic acid interactions. Methods Enzymol. 2002; 350:499-512.
17. Martin J, Masri J, Bernath A, Nishimura RN and Gera J. Hsp70 associates with Rictor and is required for mTORC2 formation and activity. Biochem Biophys Res Commun. 2008; 372(4):578-583.
18. Masri J, Bernath A, Martin J, Jo OD, Vartanian R, Funk A and Gera J. mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. Cancer Res. 2007; 67(24):11712-11720.
19. Shi Y, Sharma A, Wu H, Lichtenstein A and Gera J. Cyclin D1 and c-myc internal ribosome entry site (IRES)- dependent translation is regulated by AKT activity and enhanced by rapamycin through a p38 MAPK- and ERKdependent pathway. J Biol Chem. 2005; 280(12):10964-10973.
20. Rice RL, Rusnak JM, Yokokawa F, Yokokawa S, Messner DJ, Boynton AL, Wipf P and Lazo JS. A targeted library of small-molecule, tyrosine, and dual-specificity phosphatase inhibitors derived from a rational core design and random side chain variation. Biochemistry. 1997; 36(50):15965-15974.
21. Cloninger C, Bernath A, Bashir T, Holmes B, Artinian N, Ruegg T, Anderson L, Masri J, Lichtenstein A and Gera J. Inhibition of SAPK2/p38 enhances sensitivity to mTORC1 inhibition by blocking IRES-mediated translation initiation in glioblastoma. Molecular cancer therapeutics. 2011; 10(12):2244-2256.
22. Hsu PP, Kang SA, Rameseder J, Zhang Y, Ottina KA, Lim D, Peterson TR, Choi Y, Gray NS, Yaffe MB, Marto JA and Sabatini DM. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science. 2011; 332(6035):1317-1322.
23. Patterson KI, Brummer T, O’Brien PM and Daly RJ. Dualspecificity phosphatases: critical regulators with diverse cellular targets. Biochem J. 2009; 418(3):475-489.
24. Katagiri C, Masuda K, Urano T, Yamashita K, Araki Y, Kikuchi K and Shima H. Phosphorylation of Ser- 446 determines stability of MKP-7. J Biol Chem. 2005; 280(15):14716-14722.
25. Theodosiou A, Smith A, Gillieron C, Arkinstall S and Ashworth A. MKP5, a new member of the MAP kinase phosphatase family, which selectively dephosphorylates stress-activated kinases. Oncogene. 1999; 18(50):6981-6988.
26. Yang Q, Inoki K, Ikenoue T and Guan KL. Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev. 2006; 20(20):2820-2832.
27. Zinzalla V, Stracka D, Oppliger W and Hall MN. Activation of mTORC2 by association with the ribosome. Cell. 2011; 144(5):757-768.
28. Chalhoub N and Baker SJ. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol. 2009; 4:127-150.
29. Roux PP and Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev. 2004; 68(2):320-344.
30. Caunt CJ and Keyse SM. Dual-specificity MAP kinase phosphatases (MPKs): shaping the outcome of MAP kinase signaling. FEBS J. 2012; 280:489-504.
31. Bermudez O, Marchetti S, Pages G and Gimond C. Post-translational regulation of the ERK phosphatase DUSP6/MKP3 by the mTOR pathway. Oncogene. 2008; 27(26):3685-3691.
32. Marchetti S, Gimond C, Chambard JC, Touboul T, Roux D, Pouyssegur J and Pages G. Extracellular signal-regulated kinases phosphorylate mitogen-activated protein kinase phosphatase 3/DUSP6 at serines 159 and 197, two sites critical for its proteasomal degradation. Mol Cell Biol. 2005; 25(2):854-864.
33. Dickinson RJ, Delavaine L, Cejudo-Marin R, Stewart G, Staples CJ, Didmon MP, Trinidad AG, Alonso A, Pulido R and Keyse SM. Phosphorylation of the kinase interaction motif in mitogen-activated protein (MAP) kinase phosphatase-4 mediates cross-talk between protein kinase A and MAP kinase signaling pathways. J Biol Chem. 2011; 286(44):38018-38026.
34. Cao W, Bao C, Padalko E and Lowenstein CJ. Acetylation of mitogen-activated protein kinase phosphatase-1 inhibits Toll-like receptor signaling. J Exp Med. 2008; 205(6):1491-1503.
35. Furukawa T, Sunamura M, Motoi F, Matsuno S and Horii A. Potential Tumor Suppressive Pathway Involving DUSP6/ MKP-3 in Pancreatic Cancer. The American Journal of Pathology. 2003; 162(6):1807-1815.
36. Schullerus D, Herbers J, Chudek J, Kanamaru H and Kovacs G. Loss of heterozygosity at chromosomes 8p, 9p, and 14q is associated with stage and grade of non-papillary renal cell carcinomas. The Journal of Pathology. 1997; 183(2):151-155.
37. Emmert-Buck MR, Vocke CD, Pozzatti RO, Duray PH, Jennings SB, Florence CD, Zhuang Z, Bostwick DG, Liotta LA and Linehan WM. Allelic Loss on Chromosome 8p12– 21 in Microdissected Prostatic Intraepithelial Neoplasia. Cancer Research. 1995; 55(14):2959-2962.
38. Liao Q, Guo J, Kleeff J, Zimmermann A, Büchler MW, Korc M and Friess H. Down-regulation of the dualspecificity phosphatase MKP-1 suppresses tumorigenicity of pancreatic cancer cells. Gastroenterology. 2003; 124(7):1830-1845.
39. Sato M, Vaughan MB, Girard L, Peyton M, Lee W, Shames DS, Ramirez RD, Sunaga N, Gazdar AF, Shay JW and Minna JD. Multiple Oncogenic Changes (K-RASV12, p53 Knockdown, Mutant EGFRs, p16 Bypass, Telomerase) Are Not Sufficient to Confer a Full Malignant Phenotype on Human Bronchial Epithelial Cells. Cancer Research. 2006; 66(4):2116-2128.
40. Wang Z, Xu J, Zhou J-Y, Liu Y and Wu GS. Mitogen- Activated Protein Kinase Phosphatase-1 Is Required for Cisplatin Resistance. Cancer Research. 2006; 66(17):8870-8877.
41. Cui Y, Parra I, Zhang M, Hilsenbeck SG, Tsimelzon A, Furukawa T, Horii A, Zhang Z-Y, Nicholson RI and Fuqua SAW. Elevated Expression of Mitogen-Activated Protein Kinase Phosphatase 3 in Breast Tumors: A Mechanism of Tamoxifen Resistance. Cancer Research. 2006; 66(11):5950-5959.
42. Chan DW, Liu VWS, Tsao GSW, Yao K-M, Furukawa T, Chan KKL and Ngan HYS. Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells. Carcinogenesis. 2008; 29(9):1742-1750.